C-myc mRNA expression in epithelial ovarian carcinomas in relation to estrogen receptor status, metastatic spread, survival time, FIGO stage, and histologic grade and type

Tanner, B; Hengstler, J G; Luch, A; Meinert, R; Kreutz, E; Arand, Michael; Wilkens, C; Hofmann, M; Oesch, F; Knapstein, P G; Becker, R

doi:10.1097/00004347-199801000-00012

Citations

Citation copied

Tanner, B., Hengstler, J. G., Luch, A., Meinert, R., Kreutz, E., Arand, M., Wilkens, C., Hofmann, M., Oesch, F., Knapstein, P. G., & Becker, R. (1998). C-myc mRNA expression in epithelial ovarian carcinomas in relation to estrogen receptor status, metastatic spread, survival time, FIGO stage, and histologic grade and type. International Journal of Gynecological Pathology, 17(1), 66–74. https://doi.org/10.1097/00004347-199801000-00012

Abstract

Recently, it has been suggested that c-myc expression might correlate with estrogen receptor (ER) status and metastatic spread in ovarian cancer. In this study, expression of c-myc mRNA in 90 epithelial ovarian carcinomas was determined using the S1 nuclease protection assay. Expression of c-myc mRNA was detectable in 27 of 90 tumors. There was no significant association between c-myc mRNA expression and metastatic spread, survival time, FIGO stage, or histologic grade and type. C-myc mRNA was expressed in 45% of ER-positive tumors bu